Quantcast

Industry news that matters to you.  Learn more

The Icahn School of Medicine at Mount Sinai Uses Ayasdi for Data Analysis to Identify Subtypes of Diabetes in an Advance for Precision Medicine

Ayasdi today announced the publication of a major new finding on the sub-typing of type 2 diabetes by long-time collaborator, the Icahn School of Medicine at Mount Sinai. The findings, published in the prestigious Science journal, Science Translational Medicine, demonstrates that with the right data, technologies and researchers, precision medicine can become a reality.

Profil Institute Unites Leading Experts in Biomarker Discovery and Clinical Research to Address the Medical Challenges of NAFLD/NASH

Profil Institute for Clinical Research, a clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a collaboration of experts in biomarker discovery and clinical research in the fields of metabolism, diabetes and obesity to address the medical challenges of NAFLD and NASH.

Novo Nordisk Re-Launches Cornerstones4Care with Customized Diabetes Patient Support Program

Novo Nordisk, a world leader in diabetes care, recently announced the re-launch of Cornerstones4Care®, an award-winning online patient support platform for people living with diabetes. The diabetes support platform has been enhanced to customize the patient experience with educational resources for people at each phase of their diabetes journey while focusing on the four cornerstones of diabetes care: healthy eating, being active, medicine, and tracking.

KineMed Collaboration with Pfizer Inc. in Diabetes is Extended

KineMed Inc. recently announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. The collaboration employs KineMed’s novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

 

KineMed Announces Participation in a Global, Multi-Company Effort to Advance and Standardize a Diabetic Research Model

KineMed, Inc. announced participation in a global, two year, multi-organization effort to advance and standardize a single mouse model of early diabetic disease detection and progression. The two year effort brings together cutting edge expertise and technology with a goal to produce a new mouse research model system that can streamline the research and development of advances in diabetic research and improve the clinical success of programs using the model.